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Metastatic prostate cancer resistant to hor-
monal manipulation is considered the
advanced stage of the disease and leads to
most cancer-related mortality. With new
research focusing on modulating cancer
growth, it is essential to understand the bio-
chemical changes in cells that can then be
exploited for drug discovery and for improv-
ing responsiveness to treatment. Raman spec-
troscopy has a high chemical specificity and
can be used to detect and quantify molecular
changes at the cellular level. Collection of
large data sets generated from biological samples can be employed to form dis-
criminatory algorithms for detection of subtle and early changes in cancer cells.
The present study describes Raman finger printing of normal and metastatic
hormone-resistant prostate cancer cells including analyses with principal compo-
nent analysis and linear discrimination. Amino acid-specific signals were identi-
fied, especially loss of arginine band. Androgen-resistant prostate cancer cells
presented a higher content of phenylalanine, tyrosine, DNA and Amide III in com-
parison to PNT2 cells, which possessed greater amounts of L-arginine and had a
B conformation of DNA. The analysis utilized in this study could reliably differ-
entiate the 2 cell lines (sensitivity 95%; specificity 88%).
KEYWORDS
castrate resistant prostate cancer (CRPC), L-arginine, metastatic prostate cancer
cells, phenylalanine, Raman spectroscopy
1 | INTRODUCTION
Androgen-deprivation therapy is a mainstay management option
in men with metastatic or locally advanced prostate cancer.
Androgen-resistance (AR), alternatively known as castrate
resistant prostate cancer (CRPC), typically manifests within
12 to 18 months of initiation of treatment, however, it is a major
challenge and is responsible for the deaths of 10 000 men each
year in the United Kingdom alone. This number is projected to
increase and reach over 18.000 deaths in 2035 [1]. The mecha-
nism of hormonal resistance is complex. Normal prostate epithe-
lial cells require an optimal level of androgens to stimulate
growth. Androgen receptor-mediated signalling, through varied
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pathways, is the basis for development, differentiation and pro-
liferation of prostate cells. This is what underlies androgen dep-
rivation therapy as a primary treatment for metastatic prostate
cancer. Most patients have a favourable response to initial depri-
vation; however, relapse is very common because of cancer cells
developing resistance. Prostate cancer cells circumvent the AR
pathway and use other routes, including intracrine androgen pro-
duction, to proliferate and grow, resulting in upregulation of a
number of growth factors, proteins and pathways [2]. Analysis
of this complex environment is essential to target therapy and in
recent years, efforts have been focused on finding novel targeted
therapies for CRPC, which is not only chemoresistant but also
highly aggressive [3, 4]. Amongst a number of optical tech-
niques, Raman spectroscopy is particularly relevant for investi-
gating intracellular biochemical changes [5]. Raman
spectroscopy detects the vibrational modes of the underlying
chemical structure of a cell providing molecular signatures of
proteins, lipids and DNA without the need for a cell to be
labelled or stained [6].
Raman spectroscopy has been successfully employed in
investigating differences between normal and malignant cells
in several cancers [7–10]. In prostate cancer, it has been pri-
marily employed coupled with chemometrics as a worthwhile
diagnostic technique. Chemometrics, such as principal compo-
nent analysis (PCA) and linear discriminant analysis (LDA),
are powerful tools for analysing Raman spectra of biological
samples. Crow et al. successfully used Raman spectroscopy
and a PCA/LDA algorithm to discriminate 4 different prostate
cancer cell lines (LNCaP, PCa2b, DU145 and PC3) [11].
Further Taleb et al. acquired and analysed Raman spectra
through different multivariate statistical methods to distinguish
between immortalized normal (PNT1A) and metastatic
androgen-dependent malignant (LNCaP) prostate cells [12].
In this paper, we describe the use of Raman spectroscopy
to systematically investigate the biochemical differences
between immortalized normal prostate cells (PNT2) and meta-
static androgen-independent prostate cancer cells (DU145).
PCA of the spectra was initially performed to separate the dif-
ferent cell lines based on their molecular differences, with no
apriori assumptions. A subsequent LDA was carried out to
determine the components that better align with or discrimi-
nate between the 2 cell lines. The discrimination accuracy
based on those components was tested by with a k-fold cross
validation. The aim of this work was to gain insights into the
biochemical changes in androgen-independent prostate cancer
cells that could aid future research and therapy development.
2 | METHODS
2.1 | Cell culture and samples preparation
The immortalized normal human prostate epithelial cell line
(PNT2) was purchased from Sigma-Aldrich, USA and cultured
in Roswell Park Memorial Institute medium (RPMI-1640) con-
taining 10% foetal bovine serum (FBS) and 1% penicillin-strep-
tomycin. The human prostate androgen-independent cell line
derived from brain metastatic (DU145) was purchased from
ATCC, Manassas. and cultured in Dulbecco’s Modified Eagle
FIGURE 1 Scheme of the Raman setup used
in the study
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Medium (DMEM) supplemented with 10% FBS and 1%
penicillin-streptomycin. Cells were maintained in the incubator
under standard cell culture conditions at 37C with 5% CO2 and
90% Relative Humidity (RH), and sub-cultured every 2 days to
maintain exponential growth. The cell dissociation was pro-
cessed using 0.05% Trypsin-Ethylenediaminetetraacetic acid
(EDTA). After centrifugation to discard the trypsin supernatant,
the cells were seeded (0.8 × 106 seeding density) in 2 different
60-mm petri dishes, containing each one an autoclaved quartz
coverslip (thickness  0.15 mm). Each petri dish contained the
same amount of cells in 4 mL of culture medium. The petri
dishes were kept at ambient temperature for 30 minutes to allow
the cells to settle down and then incubated for 24 hours at cell
culture conditions. Subsequently, the culture medium in the petri
dishes was removed and the single monolayer of cells that
adhered to the quartz coverslips was washed twice with
Phosphate-buffered saline (PBS) in order to remove the remain-
ing culture medium. At this point, cells were fixed on the slides
by using a solution of 70% ethanol in deionised water. The
slides were left in the solution for 30 minutes at ambient temper-
ature and then taken out and left to dry, at 90

angle, for other
30 minutes before collecting Raman spectra from the cells.
2.2 | Raman spectroscopy instrument
Raman spectra of single cells were recorded with a custom-
made Raman setup as depicted in Figure 1. A 785-nm fibre
coupled diode laser (Sacher Lasertechnik, Marburg,
FIGURE 2 Image of a monolayer of PNT2 cells. Within the yellow box (18 μm in diameter) is the particular cell under investigation
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FIGURE 3 Average Raman spectra of PNT2
and DU145 cells. (A) Fingerprint region,
(B) protein region and (C) lipid region
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Germany) was used as excitation source (with power of
135 mW on the sample plane). The beam, reflected by a
785-nm razor edge dichroic mirror (DM), was delivered to
the sample through a 100X air microscope objective
(Mitutoyo, Japan, G Plan, numerical aperture (NA) = 0.5).
A 300-mm lens (L1) focusing on the back aperture of the
objective was employed to modify the initial beam diame-
ter. The beam, having a diameter of 2.7 mm at the output
of the fibre collimator, was decreased in size in order to be
18 μm in diameter on the sample plane. This beam size
allowed a single acquisition to represent the spectrum of a
single cell. Raman signals from single cells distributed
throughout a monolayer were collected with a 100X infinity
corrected oil immersion microscope objective (Nikon,
Tokyo, Japan, E plan, NA = 1.25) that was focused, after
cutting out more than 99.9% of the elastic scattering light
through two 785-nm notch filters (NF), onto the entrance
slit of a spectrograph (Andor Shamrock, Andor Technology
Ltd., Belfast, UK, entrance slit 200 μm, focal length
500 mm, grating 600 lines/mm). A charge-coupled device
(CCD) camera (Andor Newton DU920P-BEX2-DD, Andor
Technology Ltd., Belfast, UK) was employed for signal
detection. To image the cells, a lamp was switched on
before signal collection and a 514-nm dichroic beamsplitter
(DBS) was utilized to reflect a small amount of the visible
light towards the CCD camera.
Figure 2 presents the image of a monolayer of PNT2 cells
with the cell under investigation highlighted. The lamp was
switched off during spectra acquisition. The Raman spectra of
69 individual PNT2 cells and 74 individual DU145 cells were
acquired. In order to optimize the Raman signal and reduce the
noise, spectra were collected with a 3 seconds exposure time
and 20 accumulations. Three different spectral regions were
acquired in succession for each cell: the fingerprint region
(330–1350 cm−1), the bending region (1400–1800 cm−1) and
the stretching region (2800–3100 cm−1).
2.3 | Spectra analysis
The Raman spectra of cells were analysed by using pro-
grammes developed in the Matlab platform (Mathworks,
USA). PCA and subsequent LDA were applied to the fin-
gerprint region, from which most of the biochemical differ-
ences between the 2 cell lines emanated. PCA was applied
to reduce the number of the original variables by projecting
them onto a new Cartesian system in which the variables
are sorted in descending order of variance. The reduction of
the data sets was achieved by retaining only the principal
components (PCs) that cumulatively account for more than
95% of the variance in the original data sets. The retained
components were utilized as inputs for LDA analysis. While
PCA identified the most relevant spectral features of the
PCs, allowing the differentiation of cell types to be naturally
distinguished on the base of their biomolecular composition,
LDA determined the spectral features contained in the linear
discriminant function, which maximized the separation of
different groups of cells. Internal Matlab routines were
applied to pre-process the spectra prior to PCA/LDA analy-
sis. Each spectrum was processed to remove cosmic rays by
applying a Savitzky-Golay FIR smoothing filter which also
elevated the signal-to-noise ratio. The baseline arising from
the quartz substrate and from biological auto-fluorescence
was also subtracted. Each spectrum was then normalized to
the total area under the baseline-subtracted spectrum to
remove a source of variability between the different overall
intensities of the Raman features originating from a varying
amount of biological material in the sampling volume due
to the slightly different sizes and shapes of cells. In order to
evaluate the robustness of the PCA/LDA model a 10-fold
cross validation was carried out. For this purpose, the origi-
nal data were randomly partitioned into 10 equal-sized sub-
samples (folds). Each fold was removed from the original
data set and the remaining folds imputed in the PCA/LDA
analysis to derive the classification model. Eventually, the
signal intensities of the spectra in the removed fold were
fed into the classification model as blind values in order to
determine their classes. This procedure was repeated
TABLE 1 Raman bands assignment
Band Assignment Reference
485 Glycogen [13]
497 L-arginine [14]
621 C-C twisting mode of phenylalanine (proteins) [13]
643 C-C twisting mode of tyrosine [13]
723 DNA [8]
746 T (ring breathing mode of DNA/RNA bases) [8]
785 U,T,C (ring breathing mode of DNA/RNA
bases)
[8]
823 Out-of-plane ring breathing, tyrosine (proteins) [15]
853 Ring breathing mode of tyrosine (proteins) [13]
880 Tryptophan, δ(ring) (proteins) [16]
980 C-C stretching β-sheet (proteins) [17]
1003 Phenylalanine symmetric ring breathing
(proteins)
[18]
1031 C-H phenylalanine (proteins) [13]
1104 Phenylalanine (proteins) [19]
1158 C-C/C-N stretching (proteins) [15]
1184 Cytosine, guanine, adenine [13]
1208 C-C6H6 phenylalanine (proteins) [19]
1235 Amide III (proteins) [19]
1447 CH2 bending mode of proteins (marker for
proteins concentration)
[19]
1582 C = C bending mode of phenylalanine
(proteins)
[19]
1602 C = C bending mode of phenylalanine and
tyrosine (proteins)
[19]
1614 C = C bending mode of tyrosine and
tryptophan (proteins)
[19]
1664 Amide I (proteins) [19]
2850–2975 CH2 symmetric stretching (lipids) [19]
2910–2965 CH3 symmetric and asymmetric stretching
(lipids)
[19]
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10 times (number of folds). The average performance of the
PCA/LDA classification models was then obtained.
3 | RESULTS AND DISCUSSION
Figure 3 shows the average of the Raman spectra acquired
from PNT2 and DU145 cells (A) in the fingerprint region,
(B) in the bending region and (C) in the stretching region.
Within the fingerprint region, the mean Raman spectrum of
PNT2 and DU145 cells (see Figure 3A) features multiple
contributions from nucleic acids, proteins and lipids. The
nucleic acids bands are due to RNA and DNA bases (ade-
nine [A], thymine [T], guanine [G], cytosine [C] and uracil
[U]) and the sugar-phosphate backbone of DNA. The bands
associated with proteins are based on aromatic acids (phe-
nylalanine, tryptophan and tyrosine), amide groups of sec-
ondary protein structures and stretching or deformation of
CH and CN groups. Certain contributions from lipids are
also present. Figure 3B shows the spectral region where the
bending vibrational modes of proteins are visible, while
Figure 3C depicts the contributions of the CH stretching
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vibrational modes of lipids and proteins. Bands assignment
is summarized in Table 1.
From Figure 3B it is clear that DU145 cells have higher
protein content, as indicated by the band at 1447 cm−1,
which was identified as a marker of protein concentration
([8, 20]). The band from 1600 to 1800 cm−1 is the Amide I
band, mostly attributable to the C = O stretching vibrations
of the peptide backbone.
To identify specific constituents, the differences between
the 2 cell lines in the fingerprint region had to be considered.
Figure 4 shows the difference in spectra between the mean
spectrum of DU145 and that of PNT2 cells. Positive bands
correspond to compounds present in greater concentration in
DU145 cells, while negative bands correspond to compounds
more abundant in PNT2 cells. Positive bands are attributable
to phenylalanine (621, 1003, 1031 and 1208 cm−1) and tyro-
sine (643 and 853 cm−1). Additionally, the band associated
with DNA at 723 cm−1 is positive, meaning that greater
DNA content is present in DU145 cells. The positive band at
1081 cm−1 is because of the CN stretching modes of proteins
and CC stretching modes of lipids. Meanwhile, the positive
band at 1126 cm−1 is attributable to the stretching modes of
CN featured in proteins and to the vibrational modes of CO
present in carbohydrates. The ratio of these 2 bands repre-
sents the relative lipid/carbohydrate levels in cells [21].
The band at 497 cm−1 corresponds to L-arginine and the
band at 798 is associated with the B conformation of DNA, and
both are negative, therefore, related to PNT2 cells [12, 14].
In order to better capture the biochemical differences
between the 2 cell lines, PCA was employed to analyse the
spectra in the fingerprint region. It was found that the first
5 PCs accounted for  97% of the total spectral variability,
with the first 3 components accounting for more than 90% of
the variability. The plot of the first 3 loadings is presented in
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Figure 6. The molecular origin of the features in the compo-
nents can be assigned by comparing the known Raman shifts
(Figure 3) with the bands in the loadings. Only the bands
clearly arising from the variability in Raman intensity of the
bands in the original data sets were assigned. Bands assign-
ment can be found in Table 1. Each loading vector was
related to the original spectrum by PC scores, which refer to
the weight of that particular biochemical components in each
spectrum. In particular, a higher amount of the species giving
rise to positive bands in the loading spectrum is present in
cells to which higher scores are attributed and vice-versa:
lower amounts of the species producing negative bands can
be observed in cells with which lower scores are associated.
The score plots shown in Figure 5 highlight the natural
groupings of the each of the principal components for the cell
types. It is clear that even if the first component allows a
grouping to be made, the third component offers better dis-
crimination. The second component, shown in Figure 6B,
does not allow any form of discrimination suggesting that it
might describe intragroup variability between cells of the
same line because of different levels of phosphatidylinositol
(band at 415 cm−1) in each cell, which is particularly abun-
dant in brain cells, thiocynate (band at 445 cm−1) and glyco-
gen (band at 490 cm−1).
If the first component in Figure 5 is considered, most of
the DU145 cells have positive scores, while the entirety of
PNT2 cells have negative scores. This indicates that the spe-
cies giving rise to positive bands in the spectrum of the
loading of the first component (see Figure 6A) are present
in higher concentrations in DU145 cells, while the species
giving rise to negative bands are found at greater concentra-
tions in PNT2 cells. The spectrum of the first component is
very similar to the difference spectrum between the 2 cell
lines (see Figure 4), validating what was observed earlier:
DU145 cells have more phenylalanine, tyrosine, DNA and
Amide III, while PNT2 cells have greater levels of L-
arginine and B conformation DNA.
If the third component is considered, negative scores are
associated with DU145 cells, and positive scores with PNT2
cells. Thus, the species with positive bands in the spectrum
of the loading of the third component (see Figure 6) should
be present in higher concentrations in PNT2, while the spe-
cies giving rise to negative bands should be more abundant
in DU145 cells. This is indeed the case, the content of phe-
nylalanine (1003 and 1031 cm−1) and tyrosine (853 cm−1)
is higher in DU145 cells. Moreover, the third component
being that with better grouping between the 2 cell lines sug-
gests that the content of phenylalanine and tyrosine might
be a key factor in discriminating between them.
In order to verify which biochemical components dis-
criminate the 2 groups of cells, the 5 PCs that described the
most of the variance between the spectra were retained for
the LDA, while the less significant PCs were discarded.
While PCA retained only the PCs that described most of the
variance in the data set, LDA generated the linear discrimi-
nant function that described the most variance between the
2 different groups of cells. The distribution of LDA scores
in Figure 7A clearly reveals that the classification model
based on PCA and LDA differentiates PNT2 cells from
DU145 cells. Figure 7B features the discriminant function
vector along which the 2 cell lines are best separated. In the
LDA-function positive bands are associated with DU145
cells, while negative bands are associated with PNT2 cells.
The bands that are most relevant for the discrimination of
the 2 cell lines are those that can be assigned in the LDA-
function spectrum. Features of glycogen at 485 cm−1, phe-
nylalanine at 621, 1003 and 1031 cm−1, DNA at 723 cm−1
and nucleic acids at 1184 cm−1 were influential for the
assignment into the class DU145. On the other hand, the con-
tent of L-arginine at 497 cm−1 led to a classification of
PNT2. A 10-fold cross validation was used to predict the dis-
crimination accuracy based on the biochemical components
individuated by the PCA/LDA model as described in the
Spectra Analysis section. The original data prior to PCA
(Raman intensities of the spectra of PNT2 and DU145 cells)
were randomly partitioned into 10 equal sized folds. Each
fold was employed once as validation data in the PCA/LDA
model, while the rest of the folds were utilized as training
data. The process was iterated 10 times. The number of cor-
rectly identified cases was 132 out of 143 leading to an accu-
racy of 92.3%. The sensitivity, expressed as the number of
correctly identified cancer cells over the total number of
DU145 cells was found to be 95%. The specificity, expressed
as the number of correctly identified healthy cells over the
total number of PNT2 cells was determined to be 88%.
We also conducted a negative control test for eliminat-
ing the possibility of spurious correlations driven discrimi-
nation [22]. The spectra were assigned with different
random class labels without taking into account their true
class origins. We then repeated a 10-fold cross validation
randomly partitioning the original data set to which random
classes are assigned as described above. The process was
repeated 100 times with 100 different random class labels
vectors. We found an average correct classification rate of
50.8% with standard deviation of 4.9%. The rate of correct
classification is relatively low when compared to the 92.3%
accuracy obtained with the true class labels and it is consis-
tent with the likelihood of random selection of the true class
label, 1/2. This excludes the presence of chance correlations
in the PCA/LDA model.
The findings of the present study have implications for
future research, including in-depth mechanistic research into
changes metastatic cells acquire to adapt into new environ-
ments such as organs. Previous studies conducted by Hede-
gaard et al. [23] and Winnard Jr et al. [24] using breast cancer
isogenic cell lines have shown that this phenomenon is com-
mon, however, there are no studies in prostate cancer. Further-
more, with novel chemotherapeutic agents being introduced
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for the treatment of hormone-resistant prostate cancer, it is
important to develop and validate new technologies (such as
Raman spectroscopy) to monitor changes in the phenotype of
cells as a marker of response to these treatments.
4 | CONCLUSIONS
In this study, we used a combination of Raman spectros-
copy and PCA/LDA to investigate biochemical changes in
androgen-independent prostate cancer cells (DU145) with
respect to normal immortalized prostate cells (PNT2). A
PCA analysis was initially carried out on the spectra to
allow the 2 cell lines to be naturally discriminated on the
basis of their biochemical compositions. DU145 cells had
greater phenylalanine, tyrosine, DNA and Amide III vs
PNT2 cells, which contained more L-arginine and B confor-
mation DNA. Thereafter, LDA was conducted on the output
of the PCA to determine which biochemical species enable
discrimination between the 2 cell lines.
Higher glycogen, phenylalanine, DNA and nucleic acid
content were determinants for assigning cells to the DU145
class, while greater levels of L-arginine was decisive for
attributing cells to the PNT2 class.
Pelletier et al. and Pescador et al. demostrated in 2 inde-
pendent studies that glycogen promotes tumour growth in
low oxygen conditions [25, 26]. The potential of depriva-
tion of tyrosine and phenylalanine in treating different kind
of metastatic cancers, including prostate cancer, has been
reported in several studies [27–30]. Ma et al. observed that
L-arginine can block the formation and development of
colorectal tumours [31]. Abnormalities in arginine metabo-
lism enzymes have been observed in several types of
tumours and those cancers support biological processes by
relying on extracellular arginine. Therefore, arginine depri-
vation is currently being investigated as a novel cancer ther-
apy [32, 33]. As such, the present work has shown the
potential of Raman spectroscopy not only as diagnostic
technique, but also to detect biomolecular changes in
androgen-independent prostate cancer cells that could help
in establishing novel treatment approaches.
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